Efficacy News and Research

RSS
Study explores factors influencing countries with high rates of COVID-19 vaccine acceptance

Study explores factors influencing countries with high rates of COVID-19 vaccine acceptance

Study describes a β-CoV spike protein target for protective antibodies that may facilitate pan-β-CoV vaccine development

Study describes a β-CoV spike protein target for protective antibodies that may facilitate pan-β-CoV vaccine development

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

Study finds mRNA vaccines induce poor neutralizing antibody response against SARS-CoV-2 variants in dialysis patients

Study finds mRNA vaccines induce poor neutralizing antibody response against SARS-CoV-2 variants in dialysis patients

New research could deliver a breakthrough for kids suffering from severe form of genetic epilepsy

New research could deliver a breakthrough for kids suffering from severe form of genetic epilepsy

Nitazoxanide shows promise for COVID-19 treatment in animal model

Nitazoxanide shows promise for COVID-19 treatment in animal model

Assessing potential allergic reactions in COVID-19 vaccinated patients

Assessing potential allergic reactions in COVID-19 vaccinated patients

Real world evidence on acquired immunity from vaccines and SARS-CoV-2 infection

Real world evidence on acquired immunity from vaccines and SARS-CoV-2 infection

Ketogenic diet could enhance the efficacy of chemotherapy for pancreatic cancer, study shows

Ketogenic diet could enhance the efficacy of chemotherapy for pancreatic cancer, study shows

Stroke rehabilitation experts propose a new paradigm for improving treatment of spatial neglect

Stroke rehabilitation experts propose a new paradigm for improving treatment of spatial neglect

Newer clot-busting drug may lengthen the window for additional stroke treatment to 24 hours

Newer clot-busting drug may lengthen the window for additional stroke treatment to 24 hours

Alkem signs license agreement with Harvard to develop, commercialize new technology for treating ischemic conditions

Alkem signs license agreement with Harvard to develop, commercialize new technology for treating ischemic conditions

Screening assays identify TMPRSS2 inhibitors from drug repurposing candidates useful as COVID-19 therapeutic

Screening assays identify TMPRSS2 inhibitors from drug repurposing candidates useful as COVID-19 therapeutic

Clinical severity of COVID-19 caused by SARS-CoV-2 variants and the effectiveness of mRNA vaccines against them

Clinical severity of COVID-19 caused by SARS-CoV-2 variants and the effectiveness of mRNA vaccines against them

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

Study explores protection against Omicron and Delta infections by COVID-19 vaccination and previous infection

Study explores protection against Omicron and Delta infections by COVID-19 vaccination and previous infection

Rapid generation and evaluation of an mRNA vaccine candidate specific to Omicron

Rapid generation and evaluation of an mRNA vaccine candidate specific to Omicron

Scientists identify multi-kinase inhibitors that can effectively block SARS-CoV-2-mediated cytokine release

Scientists identify multi-kinase inhibitors that can effectively block SARS-CoV-2-mediated cytokine release

Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

Study tests efficacy of molnupiravir against SARS-CoV-2 VOCs in various animal models

Study tests efficacy of molnupiravir against SARS-CoV-2 VOCs in various animal models

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.